Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pleomorphic adenoma gene 1 (PLAG1) is a proto-oncogenic transcription factor belonging to the C2H2-type zinc finger family (UniProt Consortium, 2024, P78527). It is primarily expressed during fetal development and is typically silenced in adult tissues, but its reactivation through chromosomal rearrangements—most commonly at 8q12—is a hallmark of various neoplasms, including pleomorphic adenomas of the salivary gland and lipoblastomas (National Center for Biotechnology Information, 2024, Gene ID: 5324). PLAG1 exerts its oncogenic effects by binding to the P3 promoter of the Insulin-like growth factor 2 (IGF2) gene, leading to the overproduction of IGF2 and subsequent stimulation of cell proliferation and survival pathways (Voz et al., 2000, PubMed: 10931944). Beyond salivary gland tumors, PLAG1 dysregulation has been implicated in hepatoblastoma and certain leukemias, making it a significant biomarker for differential diagnosis (Asp et al., 2006, PubMed: 16434383). Despite its clear role in driving tumor growth, PLAG1 is currently considered a difficult-to-drug target due to the structural challenges associated with inhibiting transcription factor-DNA interactions. Therapeutic strategies are currently focused on targeting downstream effectors or utilizing novel modalities like siRNA, though no PLAG1-specific inhibitors have reached clinical approval to date (Zatkova et al., 2004, PubMed: 15131018).
Transcription factor modulation of downstream oncogenic targets such as IGF2
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pleomorphic adenoma gene 1 (PLAG1) (PLAG1).